Gland Pharma Limited (NSE: GLAND) and Ipca Laboratories Ltd. (NSE: IPCALAB) are both listed in the Medicinal Chemicals and Botanical Products industry. Gland Pharma has a market capitalisation of ₹50,589 Cr and Ipca Laboratories ₹49,470 Cr, as of 9 Nov 2026. Their P/E ratios are 49.2 and 43.4 respectively. Return on equity is 10.53% for Gland Pharma and 13.22% for Ipca Laboratories. Over one year, Gland Pharma's share price is up 70.3% and Ipca Laboratories's is up 54.2%.
| Metric | Gland Pharma | Ipca Laboratories |
|---|---|---|
| NSE Symbol | GLAND | IPCALAB |
| BSE Code | 543245 | 524494 |
| Share Price | ₹3,285.00 | ₹1,960.00 |
| Market Cap | ₹50,589 Cr | ₹49,470 Cr |
| P/E Ratio | 49.2 | 43.4 |
| Return on Equity | 10.53% | 13.22% |
| Return on Assets | 6.27% | 8.42% |
| Dividend Yield | 0.65% | 0.31% |
| Beta (1Y) | 0.49 | -0.04 |
| 1-Year Price Change | +70.3% | +54.2% |
| 3-Month Price Change | +23.2% | +16.3% |
| 52-Week Range | ₹1,573.60 – ₹3,374.00 | ₹1,293.90 – ₹2,038.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,834 Cr | ₹2,910 Cr |
| Quarterly Net Profit | ₹291 Cr | ₹389 Cr |
| Net Margin | 15.9% | 13.4% |
| EPS (Basic, Quarter) | ₹17.62 | ₹14.79 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g…
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, …
Gland Pharma has a market capitalisation of ₹50,589 Cr, against ₹49,470 Cr for Ipca Laboratories as of 9 Nov 2026, so the two are about the same size by market cap.
Gland Pharma has a P/E of 49.2 and Ipca Laboratories a P/E of 43.4 as of 9 Nov 2026.
Gland Pharma has a return on equity of 10.53% and Ipca Laboratories 13.22%.
Gland Pharma's share price is up 70.3% over one year and Ipca Laboratories's is up 54.2%.
Gland Pharma reported revenue of ₹1,834 Cr and net profit of ₹291 Cr for Q2 FY27. Ipca Laboratories reported revenue of ₹2,910 Cr and net profit of ₹389 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.